Novartis Drug Shows Success With Plaque Psorasis

by Christopher Freeburn | September 27, 2012 12:47 pm

Novartis (NYSE:NVS[1]) announced on Thursday that mid-stage drug trails of its new psoriasis treatment had proven effective.

The Swiss drug maker said that its new drug, AIN457 mitigated moderate-to-severe symptoms in people suffering from plaque psoriasis nearly three times as much as people in a control group taking a placebo.

Plaque psoriasis inflicts about 2% of the population. The condition causes scaling, pain, itching and redness on hands and feet.

The drug maker is scheduled to present detailed finding from its study later today at a medical event in the Czech Republic.

Shares of Novartis rose about 1% in Thursday mid-day trading in New York.

In July, the company won U.S. Food and Drug Administration approval for its anti-breast cancer treatment[2], Affinitor. The drug, which blocks proteins needed by cancer cells to reproduce, was derived from bacteria harvested from the soils of Easter Island.

  1. NVS:
  2. approval for its anti-breast cancer treatment:

Source URL:
Short URL: